AUG 17, 2026 · PHASE 2/3 TRIAL
Clinical Study to Evaluate the Efficacy and Safety of Huperzine A Controlled-Release Tablets in Patients With Mild-to-Moderate Dementia of the Alzheimer's Type
ClinicalTrials.gov
This is a clinical trial registry record with no reported results; the study is actively recruiting and in Phase 2/3, so only design and planned endpoints are documented.
Reported
Planned enrollment720
PhasePhase 2, Phase 3
Primary outcome measure 1ADAS-Cog11 at week 24